Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

WR Hambrecht Starts Neoforma at Strong Buy


WR Hambrecht initiated coverage of Neoforma (NEOF), a healthcare supply chain solutions company, with a strong buy rating and a $22 price target.

Analyst Sean Wieland says the strong buy rating reflects the company's growth prospects, scalable business model, discounted relative valuation. He believes positive EBITDA is just around the corner, which should once again place Neoforma on the radar screen of institutional investors who are seeking high earnings growth at reasonable valuation. Wieland says that with customers and infrastructure in place -- and expense reduction initiatives behind the company -- he thinks Neoforma is ready to return to the investor spotlight. He sees $0.27 2002 EPS on revenue of $71.1M and $0.90 2003 EPS on revenue of $97.5M.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus